Pharmaceuticals Global Industry Guide 2017

Date: May 31, 2017
Pages: 298
Price:
US$ 1,495.00 US$ 1,270.75
Offer valid until September 1, 2017!
License [?]:
Publisher: MarketLine
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P9C885257ADEN
Leaflet:

Download PDF Leaflet

Pharmaceuticals Global Industry Guide 2017

SUMMARY

Global Pharmaceuticals industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

SYNOPSIS

Essential resource for top-line data and analysis covering the global pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.

KEY HIGHLIGHTS
  • The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). Any currency conversions used in the production of this report have been calculated at constant 2016 annual average exchange rates.
  • The global pharmaceuticals market had total revenues of $946.1bn in 2016, representing a compound annual growth rate (CAGR) of 6.1% between 2012 and 2016.
  • The US, Japan and China are the largest global pharmaceutical markets followed by the four biggest European markets: France, Germany, the UK, and Italy. Amongst that number it is China that is producing the strongest growth every year, whilst the European states have been stifled due to current healthcare spending cultures in the region.
  • The patent cliff has caused revenue losses for many companies. The sales of Pfizer, Novartis and Merck & Co. fell when they lost their patents for Lipitor, Diovan and Singulair, respectively. AstraZeneca has been particularly affected by the patent cliff.
SCOPE
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the global pharmaceuticals market
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the global pharmaceuticals market
  • Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the global pharmaceuticals market with five year forecasts
REASONS TO BUY
  • What was the size of the global pharmaceuticals market by value in 2016?
  • What will be the size of the global pharmaceuticals market in 2021?
  • What factors are affecting the strength of competition in the global pharmaceuticals market?
  • How has the market performed over the last five years?
  • Who are the top competitors in the global pharmaceuticals market?
EXECUTIVE SUMMARY
Market value
Market value forecast
Geography segmentation
Market share
Introduction
What is this report about?
Who is the target reader?
How to use this report
Definitions
Global Pharmaceuticals
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Pharmaceuticals in Asia-Pacific
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Pharmaceuticals in Europe
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Pharmaceuticals in France
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in Germany
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in Italy
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in Japan
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in Australia
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in Canada
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in China
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in The Netherlands
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in Spain
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in The United Kingdom
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in The United States
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Company Profiles
Leading companies
Appendix
Methodology
About MarketLine

LIST OF TABLES

Table 1: Global pharmaceuticals market value: $ billion, 2012–16
Table 2: Global pharmaceuticals market geography segmentation: $ billion, 2016
Table 3: Global pharmaceuticals market share: % share, by value, 2016
Table 4: Global pharmaceuticals market value forecast: $ billion, 2016–21
Table 5: Asia-Pacific pharmaceuticals market value: $ billion, 2012–16
Table 6: Asia–Pacific pharmaceuticals market geography segmentation: $ billion, 2016
Table 7: Asia-Pacific pharmaceuticals market share: % share, by value, 2016
Table 8: Asia-Pacific pharmaceuticals market value forecast: $ billion, 2016–21
Table 9: Europe pharmaceuticals market value: $ billion, 2012–16
Table 10: Europe pharmaceuticals market geography segmentation: $ billion, 2016
Table 11: Europe pharmaceuticals market share: % share, by value, 2016
Table 12: Europe pharmaceuticals market value forecast: $ billion, 2016–21
Table 13: France pharmaceuticals market value: $ billion, 2012–16
Table 14: France pharmaceuticals market geography segmentation: $ billion, 2016
Table 15: France pharmaceuticals market share: % share, by value, 2016
Table 16: France pharmaceuticals market value forecast: $ billion, 2016–21
Table 17: France size of population (million), 2012–16
Table 18: France gdp (constant 2005 prices, $ billion), 2012–16
Table 19: France gdp (current prices, $ billion), 2012–16
Table 20: France inflation, 2012–16
Table 21: France consumer price index (absolute), 2012–16
Table 22: France exchange rate, 2012–16
Table 23: Germany pharmaceuticals market value: $ billion, 2012–16
Table 24: Germany pharmaceuticals market geography segmentation: $ billion, 2016
Table 25: Germany pharmaceuticals market share: % share, by value, 2016
Table 26: Germany pharmaceuticals market value forecast: $ billion, 2016–21
Table 27: Germany size of population (million), 2012–16
Table 28: Germany gdp (constant 2005 prices, $ billion), 2012–16
Table 29: Germany gdp (current prices, $ billion), 2012–16
Table 30: Germany inflation, 2012–16
Table 31: Germany consumer price index (absolute), 2012–16
Table 32: Germany exchange rate, 2012–16
Table 33: Italy pharmaceuticals market value: $ billion, 2012–16
Table 34: Italy pharmaceuticals market geography segmentation: $ billion, 2016
Table 35: Italy pharmaceuticals market share: % share, by value, 2016
Table 36: Italy pharmaceuticals market value forecast: $ billion, 2016–21
Table 37: Italy size of population (million), 2012–16
Table 38: Italy gdp (constant 2005 prices, $ billion), 2012–16
Table 39: Italy gdp (current prices, $ billion), 2012–16
Table 40: Italy inflation, 2012–16
Table 41: Italy consumer price index (absolute), 2012–16
Table 42: Italy exchange rate, 2012–16
Table 43: Japan pharmaceuticals market value: $ billion, 2012–16
Table 44: Japan pharmaceuticals market geography segmentation: $ billion, 2016
Table 45: Japan pharmaceuticals market share: % share, by value, 2016
Table 46: Japan pharmaceuticals market value forecast: $ billion, 2016–21
Table 47: Japan size of population (million), 2012–16
Table 48: Japan gdp (constant 2005 prices, $ billion), 2012–16
Table 49: Japan gdp (current prices, $ billion), 2012–16
Table 50: Japan inflation, 2012–16
Table 51: Japan consumer price index (absolute), 2012–16
Table 52: Japan exchange rate, 2012–16
Table 53: Australia pharmaceuticals market value: $ billion, 2012–16
Table 54: Australia pharmaceuticals market geography segmentation: $ billion, 2016
Table 55: Australia pharmaceuticals market share: % share, by value, 2016
Table 56: Australia pharmaceuticals market value forecast: $ billion, 2016–21
Table 57: Australia size of population (million), 2012–16
Table 58: Australia gdp (constant 2005 prices, $ billion), 2012–16
Table 59: Australia gdp (current prices, $ billion), 2012–16
Table 60: Australia inflation, 2012–16
Table 61: Australia consumer price index (absolute), 2012–16
Table 62: Australia exchange rate, 2012–16
Table 63: Canada pharmaceuticals market value: $ billion, 2012–16
Table 64: Canada pharmaceuticals market geography segmentation: $ billion, 2016
Table 65: Canada pharmaceuticals market share: % share, by value, 2016
Table 66: Canada pharmaceuticals market value forecast: $ billion, 2016–21
Table 67: Canada size of population (million), 2012–16
Table 68: Canada gdp (constant 2005 prices, $ billion), 2012–16
Table 69: Canada gdp (current prices, $ billion), 2012–16
Table 70: Canada inflation, 2012–16
Table 71: Canada consumer price index (absolute), 2012–16
Table 72: Canada exchange rate, 2012–16
Table 73: China pharmaceuticals market value: $ billion, 2012–16
Table 74: China pharmaceuticals market geography segmentation: $ billion, 2016
Table 75: China pharmaceuticals market share: % share, by value, 2016
Table 76: China pharmaceuticals market value forecast: $ billion, 2016–21
Table 77: China size of population (million), 2012–16
Table 78: China gdp (constant 2005 prices, $ billion), 2012–16
Table 79: China gdp (current prices, $ billion), 2012–16
Table 80: China inflation, 2012–16
Table 81: China consumer price index (absolute), 2012–16
Table 82: China exchange rate, 2012–16
Table 83: Netherlands pharmaceuticals market value: $ billion, 2012–16
Table 84: Netherlands pharmaceuticals market geography segmentation: $ billion, 2016
Table 85: Netherlands pharmaceuticals market share: % share, by value, 2016
Table 86: Netherlands pharmaceuticals market value forecast: $ billion, 2016–21
Table 87: Netherlands size of population (million), 2012–16
Table 88: Netherlands gdp (constant 2005 prices, $ billion), 2012–16
Table 89: Netherlands gdp (current prices, $ billion), 2012–16
Table 90: Netherlands inflation, 2012–16
Table 91: Netherlands consumer price index (absolute), 2012–16
Table 92: Netherlands exchange rate, 2012–16
Table 93: Spain pharmaceuticals market value: $ billion, 2012–16
Table 94: Spain pharmaceuticals market geography segmentation: $ billion, 2016
Table 95: Spain pharmaceuticals market share: % share, by value, 2016
Table 96: Spain pharmaceuticals market value forecast: $ billion, 2016–21
Table 97: Spain size of population (million), 2012–16
Table 98: Spain gdp (constant 2005 prices, $ billion), 2012–16
Table 99: Spain gdp (current prices, $ billion), 2012–16
Table 100: Spain inflation, 2012–16
Table 101: Spain consumer price index (absolute), 2012–16
Table 102: Spain exchange rate, 2012–16
Table 103: United Kingdom pharmaceuticals market value: $ billion, 2012–16
Table 104: United Kingdom pharmaceuticals market geography segmentation: $ billion, 2016
Table 105: United Kingdom pharmaceuticals market share: % share, by value, 2016
Table 106: United Kingdom pharmaceuticals market value forecast: $ billion, 2016–21
Table 107: United Kingdom size of population (million), 2012–16
Table 108: United Kingdom gdp (constant 2005 prices, $ billion), 2012–16
Table 109: United Kingdom gdp (current prices, $ billion), 2012–16
Table 110: United Kingdom inflation, 2012–16
Table 111: United Kingdom consumer price index (absolute), 2012–16
Table 112: United Kingdom exchange rate, 2012–16
Table 113: United States pharmaceuticals market value: $ billion, 2012–16
Table 114: United States pharmaceuticals market geography segmentation: $ billion, 2016
Table 115: United States pharmaceuticals market share: % share, by value, 2016
Table 116: United States pharmaceuticals market value forecast: $ billion, 2016–21
Table 117: United States size of population (million), 2012–16
Table 118: United States gdp (constant 2005 prices, $ billion), 2012–16
Table 119: United States gdp (current prices, $ billion), 2012–16
Table 120: United States inflation, 2012–16
Table 121: United States consumer price index (absolute), 2012–16
Table 122: United States exchange rate, 2012–15
Table 123: Bayer AG: key facts
Table 124: Bayer AG: key financials ($)
Table 125: Bayer AG: key financials (€)
Table 126: Bayer AG: key financial ratios
Table 127: Johnson & Johnson: key facts
Table 128: Johnson & Johnson: key financials ($)
Table 129: Johnson & Johnson: key financial ratios
Table 130: Pfizer Inc.: key facts
Table 131: Pfizer Inc.: key financials ($)
Table 132: Pfizer Inc.: key financial ratios
Table 133: Daiichi Sankyo Co., Ltd.: key facts
Table 134: Daiichi Sankyo Co., Ltd.: key financials ($)
Table 135: Daiichi Sankyo Co., Ltd.: key financials (¥)
Table 136: Daiichi Sankyo Co., Ltd.: key financial ratios
Table 137: Takeda Pharmaceutical Company Limited: key facts
Table 138: Takeda Pharmaceutical Company Limited: key financials ($)
Table 139: Takeda Pharmaceutical Company Limited: key financials (¥)
Table 140: Takeda Pharmaceutical Company Limited: key financial ratios
Table 141: Yangtze River Pharmaceutical Group: key facts
Table 142: Laboratoires Pierre Fabre SA: key facts
Table 143: Sanofi SA: key facts
Table 144: Sanofi SA: key financials ($)
Table 145: Sanofi SA: key financials (€)
Table 146: Sanofi SA: key financial ratios
Table 147: Les Laboratoires Servier: key facts
Table 148: Boehringer Ingelheim GmbH: key facts
Table 149: Boehringer Ingelheim GmbH: key financials ($)
Table 150: Boehringer Ingelheim GmbH: key financials (€)
Table 151: Boehringer Ingelheim GmbH: key financial ratios
Table 152: Novartis AG: key facts
Table 153: Novartis AG: key financials ($)
Table 154: Novartis AG: key financial ratios
Table 155: F. Hoffmann-La Roche Ltd: key facts
Table 156: F. Hoffmann-La Roche Ltd: key financials ($)
Table 157: F. Hoffmann-La Roche Ltd: key financials (CHF)
Table 158: F. Hoffmann-La Roche Ltd: key financial ratios
Table 159: Chiesi Farmaceutici S.p.A.: key facts
Table 160: The Menarini Group: key facts
Table 161: Recordati S.p.A.: key facts
Table 162: Astellas Pharma Inc.: key facts
Table 163: Astellas Pharma Inc.: key financials ($)
Table 164: Astellas Pharma Inc.: key financials (¥)
Table 165: Astellas Pharma Inc.: key financial ratios
Table 166: Mitsubishi Tanabe Pharma Corporation: key facts
Table 167: Mitsubishi Tanabe Pharma Corporation: key financials ($)
Table 168: Mitsubishi Tanabe Pharma Corporation: key financials (¥)
Table 169: Mitsubishi Tanabe Pharma Corporation: key financial ratios
Table 170: Aspen Pharmacare Holdings Ltd: key facts
Table 171: Aspen Pharmacare Holdings Ltd: key financials ($)
Table 172: Aspen Pharmacare Holdings Ltd: key financials (ZAR)
Table 173: Aspen Pharmacare Holdings Ltd: key financial ratios
Table 174: GlaxoSmithKline Plc: key facts
Table 175: GlaxoSmithKline Plc: key financials ($)
Table 176: GlaxoSmithKline Plc: key financials (£)
Table 177: GlaxoSmithKline Plc: key financial ratios
Table 178: Apotex, Inc.: key facts
Table 179: Merck & Co., Inc.: key facts
Table 180: Merck & Co., Inc.: key financials ($)
Table 181: Merck & Co., Inc.: key financial ratios
Table 182: Guangzhou Pharmaceutical Holdings Limited: key facts
Table 183: Shanghai Pharmaceuticals Holding Co Ltd: key facts
Table 184: Shanghai Pharmaceuticals Holding Co Ltd: key financials ($)
Table 185: Shanghai Pharmaceuticals Holding Co Ltd: key financials (CNY)
Table 186: Shanghai Pharmaceuticals Holding Co Ltd: key financial ratios
Table 187: Yunnan Baiyao Group Co., Ltd.: key facts
Table 188: Yunnan Baiyao Group Co., Ltd.: key financials ($)
Table 189: Yunnan Baiyao Group Co., Ltd.: key financials (CNY)
Table 190: Yunnan Baiyao Group Co., Ltd.: key financial ratios
Table 191: Almirall S.A.: key facts
Table 192: Almirall S.A.: key financials ($)
Table 193: Almirall S.A.: key financials (€)
Table 194: Almirall S.A.: key financial ratios
Table 195: AstraZeneca PLC: key facts
Table 196: AstraZeneca PLC: key financials ($)
Table 197: AstraZeneca PLC: key financial ratios

LIST OF FIGURES

Figure 1: Global pharmaceuticals market value: $ billion, 2012–16
Figure 2: Global pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 3: Global pharmaceuticals market share: % share, by value, 2016
Figure 4: Global pharmaceuticals market value forecast: $ billion, 2016–21
Figure 5: Forces driving competition in the global pharmaceuticals market, 2016
Figure 6: Drivers of buyer power in the global pharmaceuticals market, 2016
Figure 7: Drivers of supplier power in the global pharmaceuticals market, 2016
Figure 8: Factors influencing the likelihood of new entrants in the global pharmaceuticals market, 2016
Figure 9: Factors influencing the threat of substitutes in the global pharmaceuticals market, 2016
Figure 10: Drivers of degree of rivalry in the global pharmaceuticals market, 2016
Figure 11: Asia-Pacific pharmaceuticals market value: $ billion, 2012–16
Figure 12: Asia–Pacific pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 13: Asia-Pacific pharmaceuticals market share: % share, by value, 2016
Figure 14: Asia-Pacific pharmaceuticals market value forecast: $ billion, 2016–21
Figure 15: Forces driving competition in the pharmaceuticals market in Asia-Pacific, 2016
Figure 16: Drivers of buyer power in the pharmaceuticals market in Asia-Pacific, 2016
Figure 17: Drivers of supplier power in the pharmaceuticals market in Asia-Pacific, 2016
Figure 18: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Asia-Pacific, 2016
Figure 19: Factors influencing the threat of substitutes in the pharmaceuticals market in Asia-Pacific, 2016
Figure 20: Drivers of degree of rivalry in the pharmaceuticals market in Asia-Pacific, 2016
Figure 21: Europe pharmaceuticals market value: $ billion, 2012–16
Figure 22: Europe pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 23: Europe pharmaceuticals market share: % share, by value, 2016
Figure 24: Europe pharmaceuticals market value forecast: $ billion, 2016–21
Figure 25: Forces driving competition in the pharmaceuticals market in Europe, 2016
Figure 26: Drivers of buyer power in the pharmaceuticals market in Europe, 2016
Figure 27: Drivers of supplier power in the pharmaceuticals market in Europe, 2016
Figure 28: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Europe, 2016
Figure 29: Factors influencing the threat of substitutes in the pharmaceuticals market in Europe, 2016
Figure 30: Drivers of degree of rivalry in the pharmaceuticals market in Europe, 2016
Figure 31: France pharmaceuticals market value: $ billion, 2012–16
Figure 32: France pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 33: France pharmaceuticals market share: % share, by value, 2016
Figure 34: France pharmaceuticals market value forecast: $ billion, 2016–21
Figure 35: Forces driving competition in the pharmaceuticals market in France, 2016
Figure 36: Drivers of buyer power in the pharmaceuticals market in France, 2016
Figure 37: Drivers of supplier power in the pharmaceuticals market in France, 2016
Figure 38: Factors influencing the likelihood of new entrants in the pharmaceuticals market in France, 2016
Figure 39: Factors influencing the threat of substitutes in the pharmaceuticals market in France, 2016
Figure 40: Drivers of degree of rivalry in the pharmaceuticals market in France, 2016
Figure 41: Germany pharmaceuticals market value: $ billion, 2012–16
Figure 42: Germany pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 43: Germany pharmaceuticals market share: % share, by value, 2016
Figure 44: Germany pharmaceuticals market value forecast: $ billion, 2016–21
Figure 45: Forces driving competition in the pharmaceuticals market in Germany, 2016
Figure 46: Drivers of buyer power in the pharmaceuticals market in Germany, 2016
Figure 47: Drivers of supplier power in the pharmaceuticals market in Germany, 2016
Figure 48: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Germany, 2016
Figure 49: Factors influencing the threat of substitutes in the pharmaceuticals market in Germany, 2016
Figure 50: Drivers of degree of rivalry in the pharmaceuticals market in Germany, 2016
Figure 51: Italy pharmaceuticals market value: $ billion, 2012–16
Figure 52: Italy pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 53: Italy pharmaceuticals market share: % share, by value, 2016
Figure 54: Italy pharmaceuticals market value forecast: $ billion, 2016–21
Figure 55: Forces driving competition in the pharmaceuticals market in Italy, 2016
Figure 56: Drivers of buyer power in the pharmaceuticals market in Italy, 2016
Figure 57: Drivers of supplier power in the pharmaceuticals market in Italy, 2016
Figure 58: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Italy, 2016
Figure 59: Factors influencing the threat of substitutes in the pharmaceuticals market in Italy, 2016
Figure 60: Drivers of degree of rivalry in the pharmaceuticals market in Italy, 2016
Figure 61: Japan pharmaceuticals market value: $ billion, 2012–16
Figure 62: Japan pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 63: Japan pharmaceuticals market share: % share, by value, 2016
Figure 64: Japan pharmaceuticals market value forecast: $ billion, 2016–21
Figure 65: Forces driving competition in the pharmaceuticals market in Japan, 2016
Figure 66: Drivers of buyer power in the pharmaceuticals market in Japan, 2016
Figure 67: Drivers of supplier power in the pharmaceuticals market in Japan, 2016
Figure 68: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Japan, 2016
Figure 69: Factors influencing the threat of substitutes in the pharmaceuticals market in Japan, 2016
Figure 70: Drivers of degree of rivalry in the pharmaceuticals market in Japan, 2016
Figure 71: Australia pharmaceuticals market value: $ billion, 2012–16
Figure 72: Australia pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 73: Australia pharmaceuticals market share: % share, by value, 2016
Figure 74: Australia pharmaceuticals market value forecast: $ billion, 2016–21
Figure 75: Forces driving competition in the pharmaceuticals market in Australia, 2016
Figure 76: Drivers of buyer power in the pharmaceuticals market in Australia, 2016
Figure 77: Drivers of supplier power in the pharmaceuticals market in Australia, 2016
Figure 78: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Australia, 2016
Figure 79: Factors influencing the threat of substitutes in the pharmaceuticals market in Australia, 2016
Figure 80: Drivers of degree of rivalry in the pharmaceuticals market in Australia, 2016
Figure 81: Canada pharmaceuticals market value: $ billion, 2012–16
Figure 82: Canada pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 83: Canada pharmaceuticals market share: % share, by value, 2016
Figure 84: Canada pharmaceuticals market value forecast: $ billion, 2016–21
Figure 85: Forces driving competition in the pharmaceuticals market in Canada, 2016
Figure 86: Drivers of buyer power in the pharmaceuticals market in Canada, 2016
Figure 87: Drivers of supplier power in the pharmaceuticals market in Canada, 2016
Figure 88: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2016
Figure 89: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2016
Figure 90: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2016
Figure 91: China pharmaceuticals market value: $ billion, 2012–16
Figure 92: China pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 93: China pharmaceuticals market share: % share, by value, 2016
Figure 94: China pharmaceuticals market value forecast: $ billion, 2016–21
Figure 95: Forces driving competition in the pharmaceuticals market in China, 2016
Figure 96: Drivers of buyer power in the pharmaceuticals market in China, 2016
Figure 97: Drivers of supplier power in the pharmaceuticals market in China, 2016
Figure 98: Factors influencing the likelihood of new entrants in the pharmaceuticals market in China, 2016
Figure 99: Factors influencing the threat of substitutes in the pharmaceuticals market in China, 2016
Figure 100: Drivers of degree of rivalry in the pharmaceuticals market in China, 2016
Figure 101: Netherlands pharmaceuticals market value: $ billion, 2012–16
Figure 102: Netherlands pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 103: Netherlands pharmaceuticals market share: % share, by value, 2016
Figure 104: Netherlands pharmaceuticals market value forecast: $ billion, 2016–21
Figure 105: Forces driving competition in the pharmaceuticals market in the Netherlands, 2016
Figure 106: Drivers of buyer power in the pharmaceuticals market in the Netherlands, 2016
Figure 107: Drivers of supplier power in the pharmaceuticals market in the Netherlands, 2016
Figure 108: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the Netherlands, 2016
Figure 109: Factors influencing the threat of substitutes in the pharmaceuticals market in the Netherlands, 2016
Figure 110: Drivers of degree of rivalry in the pharmaceuticals market in the Netherlands, 2016
Figure 111: Spain pharmaceuticals market value: $ billion, 2012–16
Figure 112: Spain pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 113: Spain pharmaceuticals market share: % share, by value, 2016
Figure 114: Spain pharmaceuticals market value forecast: $ billion, 2016–21
Figure 115: Forces driving competition in the pharmaceuticals market in Spain, 2016
Figure 116: Drivers of buyer power in the pharmaceuticals market in Spain, 2016
Figure 117: Drivers of supplier power in the pharmaceuticals market in Spain, 2016
Figure 118: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Spain, 2016
Figure 119: Factors influencing the threat of substitutes in the pharmaceuticals market in Spain, 2016
Figure 120: Drivers of degree of rivalry in the pharmaceuticals market in Spain, 2016
Figure 121: United Kingdom pharmaceuticals market value: $ billion, 2012–16
Figure 122: United Kingdom pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 123: United Kingdom pharmaceuticals market share: % share, by value, 2016
Figure 124: United Kingdom pharmaceuticals market value forecast: $ billion, 2016–21
Figure 125: Forces driving competition in the pharmaceuticals market in the United Kingdom, 2016
Figure 126: Drivers of buyer power in the pharmaceuticals market in the United Kingdom, 2016
Figure 127: Drivers of supplier power in the pharmaceuticals market in the United Kingdom, 2016
Figure 128: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United Kingdom, 2016
Figure 129: Factors influencing the threat of substitutes in the pharmaceuticals market in the United Kingdom, 2016
Figure 130: Drivers of degree of rivalry in the pharmaceuticals market in the United Kingdom, 2016
Figure 131: United States pharmaceuticals market value: $ billion, 2012–16
Figure 132: United States pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 133: United States pharmaceuticals market share: % share, by value, 2016
Figure 134: United States pharmaceuticals market value forecast: $ billion, 2016–21
Figure 135: Forces driving competition in the pharmaceuticals market in the United States, 2016
Figure 136: Drivers of buyer power in the pharmaceuticals market in the United States, 2016
Figure 137: Drivers of supplier power in the pharmaceuticals market in the United States, 2016
Figure 138: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2016
Figure 139: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2016
Figure 140: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2016
Figure 141: Bayer AG: revenues & profitability
Figure 142: Bayer AG: assets & liabilities
Figure 143: Johnson & Johnson: revenues & profitability
Figure 144: Johnson & Johnson: assets & liabilities
Figure 145: Pfizer Inc.: revenues & profitability
Figure 146: Pfizer Inc.: assets & liabilities
Figure 147: Daiichi Sankyo Co., Ltd.: revenues & profitability
Figure 148: Daiichi Sankyo Co., Ltd.: assets & liabilities
Figure 149: Takeda Pharmaceutical Company Limited: revenues & profitability
Figure 150: Takeda Pharmaceutical Company Limited: assets & liabilities
Figure 151: Sanofi SA: revenues & profitability
Figure 152: Sanofi SA: assets & liabilities
Figure 153: Boehringer Ingelheim GmbH: revenues & profitability
Figure 154: Boehringer Ingelheim GmbH: assets & liabilities
Figure 155: Novartis AG: revenues & profitability
Figure 156: Novartis AG: assets & liabilities
Figure 157: F. Hoffmann-La Roche Ltd: revenues & profitability
Figure 158: F. Hoffmann-La Roche Ltd: assets & liabilities
Figure 159: Astellas Pharma Inc.: revenues & profitability
Figure 160: Astellas Pharma Inc.: assets & liabilities
Figure 161: Mitsubishi Tanabe Pharma Corporation: revenues & profitability
Figure 162: Mitsubishi Tanabe Pharma Corporation: assets & liabilities
Figure 163: Aspen Pharmacare Holdings Ltd: revenues & profitability
Figure 164: Aspen Pharmacare Holdings Ltd: assets & liabilities
Figure 165: GlaxoSmithKline Plc: revenues & profitability
Figure 166: GlaxoSmithKline Plc: assets & liabilities
Figure 167: Merck & Co., Inc.: revenues & profitability
Figure 168: Merck & Co., Inc.: assets & liabilities
Figure 169: Shanghai Pharmaceuticals Holding Co Ltd: revenues & profitability
Figure 170: Shanghai Pharmaceuticals Holding Co Ltd: assets & liabilities
Figure 171: Yunnan Baiyao Group Co., Ltd.: revenues & profitability
Figure 172: Yunnan Baiyao Group Co., Ltd.: assets & liabilities
Figure 173: Almirall S.A.: revenues & profitability
Figure 174: Almirall S.A.: assets & liabilities
Figure 175: AstraZeneca PLC: revenues & profitability
Figure 176: AstraZeneca PLC: assets & liabilities
Skip to top


Ask Your Question

Pharmaceuticals Global Industry Guide 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: